News Column

Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae

September 3, 2014

CINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene®molecular menu of teststo its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasmapneumoniae on the illumigene molecular platform without individual negotiations.

Premier’s mission is “to improve the health of communities” and using the power of collaboration to lead the transformation to high-quality, cost-effective care aligns with Meridian’s promise to provide a new standard for patient care with our innovative diagnostic testing solutions such as the illumigene molecular system. The illumigene molecular system utilizes loop-mediated isothermal DNA amplification (LAMP) technology, an efficient system which allows Meridian to provide customers the illumipro–10™ instrument without a capital investment or costly annual service contract. The illumigene procedure is simple, highly sensitive, and yields results in less than one hour, which helps drive improvements in the early diagnosis and treatment of preventable diseases.

Mike Shaughnessy, President of Global Diagnostics at Meridian Bioscience, commented, “This is an exciting opportunity for Meridian to coordinate with Premier to place our complete illumigene molecular menu in member facilities. Meridian is privileged to collaborate with Premier to assist its alliance members in their efforts to deliver improved clinical outcomes, improve operating efficiencies, and reduce costs in their facilities.”

About Premier, Inc.

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 3,000 U.S. hospitals and more than 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier’s blog for more information about the company.

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.



Meridian Bioscience Inc.

John A. Kraeutler, Chief Executive Officer, 513-271-3700

Source: Meridian Bioscience Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Business Wire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters